Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Polio Immunity
Interventions
DRUG

IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose

Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.

Trial Locations (1)

23507

C3ID Clinic, Eastern Virginia Medical School, Norfolk

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NanoPass Technologies Ltd

INDUSTRY

lead

Eastern Virginia Medical School

OTHER

NCT01686503 - Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects | Biotech Hunter | Biotech Hunter